Nutrition, Metabolism & Cardiovascular Diseases
Volume 20, Issue 6 , Pages 451-458 , July 2010

Postmenopausal hormone therapy and cardiovascular disease in women

Received 27 January 2010 ,Revised 18 February 2010 ,Accepted 18 February 2010.

References 

  1. The Writing Group for the Women's Health Initiative . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative. JAMA. 2002;288:321–333
  2. The Women's Health Initiative Steering Committee . Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004;291:1701–1712
  3. Heiss G, Wallace R, Anderson GL, Aragaki A, Beresford SAA, Brzyski R, et al. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA. 2008;299:1036–1045
  4. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 2003;349:523–534
  5. Wassertheil-Smoller S, Hendrix S, Limacher M, Heiss F, Kooperberg C, Baird A, et al. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA. 2003;289:2673–2684
  6. Hendrix SL, Wassertheil-Smoller S, Johnson KC, Howard BV, Kooperberg C, Rossouw JE, et al. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation. 2006;113:2425–2434
  7. Barrett-Connor E, Grady D. Hormone replacement therapy, heart disease and other considerations. Ann Rev Public Health. 1998;19:55–72
  8. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med. 1999;340:1801–1811
  9. Lenfant C. Statement from Claude Lenfant, MD, NHLBI Director, on preliminary trends in the Women's Health Initiative. NHLBI Communications Office; April 3, 2000;
  10. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280(7):605–613
  11. Mikkola TS, Clarkson TB. Estrogen replacement therapy, atherosclerosis, and vascular function. Cardiovasc Res. 2002;53:605–619
  12. Hsia J, Langer RD, Manson JE, Kuller L, Johnson KC, Hendrix SL, et al. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med. 2006;166:357–365
  13. Rossouw JE, Prentice RL, Manson JE, Wu LL, Barad D, Barnabei V, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297:1465–1477
  14. Manson JE, Allison MA, Rossouw JE, Carr JJ, Langer RD, Hsia J, et al. Estrogen therapy and coronary–artery calcification. N Engl J Med. 2007;356:2591–2602
  15. Mendelsohn ME, Karas RH. HRT and the young at heart. N Engl J Med. 2007;356:2639–2641
  16. Barrett-Connor E. An epidemiologist looks at hormones and heart disease in women. J Clin Endocr Metab. 2003;88:4031–4042
  17. Kalin MF, Zumoff B. Sex hormones and coronary disease: a review of the clinical studies. Steroids. 1990;55:330–352
  18. Hazzard WR, Applebaum-Bowden D. Why women live longer than men: the biological mechanism of the sex differential in longevity. Trans Am Clin Climatol Assoc. 1990;101:168–189
  19. Holden C. Can smoking explain the ultimate gender gap?. Science. 1983;221:1034
  20. Bush TL, Barrett-Connor E. Noncontraceptive estrogen use and cardiovascular disease. Epidemiol Rev. 1985;7:80–104
  21. The Coronary Drug Project Research Group . The Coronary Drug Project: initial findings leading to modifications of its research protocol. JAMA. 1970;214:1303–1313
  22. The Coronary Drug Project Research Group . The Coronary Drug Project: findings leading to discontinuation of the 2.4mg day estrogen group. JAMA. 1973;226:652–657
  23. Schrogie JJ, Solomon HM. Estrogenic hormones and blood coagulation. J Chron Dis. 1967;20:675–678
  24. Kannel WB. Oral contraceptive hypertension and thromboembolism. Int J Gynaecol Obstet. 1979;16:466–472
  25. Stefanick ML. Estrogens and progestins: background and history, trends in use, and guideline and regimens approved by the US Food and Drug Administration. Am J Med. 2005;118:64S–73S
  26. Grady D, Hulley SB, Furberg C. Venous thromboembolic events associated with hormone replacement therapy. JAMA. 1997;278:477
  27. Lipid Research Clinics Prevalence Survey . The lipid research clinics: population studies data book. The prevalence study. vol. 1. US Dept Heath and Human Services; 1980;NIH Pub No 80: 1527
  28. Rifkind BM, Segal P. Lipid research clinics program reference values for hyperlipidemia and hypolipidemia. JAMA. 1983;250:1869–1872
  29. Wenger N. Clinical characteristics of coronary heart disease in women: emphasis on gender differences. Cardiovasc Res. 2002;53:538–567
  30. Tunstall-Pedoe H. Myth and paradox of coronary risk and the menopause. Lancet. 1998;351:1425–1437
  31. Barrett-Connor E. Sex differences in coronary heart disease. Why are women so superior? The 1995 Ancel Keys Lecture. Circulation. 1997;95:252–264
  32. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225–249
  33. Vaccarino V, Krumholz HM, Yarzebski J, Gore JM, Goldberg RJ. Sex differences in 2-year mortality after hospital discharge for myocardial infarction. Ann Intern Med. 2001;134:1730181
  34. Regitz-Zagrosek V. Therapeutic implications of the gender-specific aspects of cardiovascular disease. Nat Rev Drug Discov. 2006;5:425–438Review
  35. Pilote L, Dasgupta K, Guru V, Humphries KH, McGrath J, Norris C, et al. A comprehensive view of sex-specific issues related to cardiovascular disease. CMAJ. 2007;176(6):S1–S44
  36. Smith DC, Prentice R, Thompson DJ, Herrmann WL. Association of exogenous estrogen and endometrial carcinoma. N Engl J Med. 1975;293:1164–1167
  37. Ziel HK, Finkle WD. Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med. 1975;293:1167–1170
  38. Writing Group for the PEPI Trial . Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA. 1996;275:370–375
  39. Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol. 1995;85:304–313
  40. Bush TL, Cowan LD, Barrett-Connor E, Criqui MH, Karon JM, Wallace RB, et al. Mortality: preliminary results from the lipid research clinics program follow-up study. JAMA. 1983;249:903–906
  41. Wilson PW, Garrison RF, Castelli WP. Postmenopausal estrogen use, cigarette smoking, and cardiovascular mortality in women over 50: The Framingham Study. N Engl J Med. 1985;313:1938–1943
  42. Stampfer MJ, Willett WC, Colditz GA, Rosner B, Speizer FE, Hennekens CH. A prospective study of postmenopausal estrogen therapy and coronary heart disease. N Engl J Med. 1985;313:1944–1949
  43. Bush TL, Barrett-Connor E, Cowan LD, Criqui MH, Wallace RB, Suchindran CM, et al. Cardiovascular mortality and noncrotraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation. 1987;75:1102–1109
  44. Petitti DB, Perlman JA, Sidney S. Noncontraceptive estrogen and mortality: long-term follow-up of women in the Walnut Creek Study. Obstet Gynecol. 1987;70:289–293
  45. Henderson BE, Paganini-Hill A, Ross RK. Estrogen replacement therapy and protection from acute myocardial infarction. Am J Obstet Gynecol. 1988;159:312–317
  46. Barrett-Connor E, Bush TL. Estrogen and coronary heart disease in women. JAMA. 1991;265:1861–1867
  47. American College of Physicians . Guidelines for counseling postmenopausal women about preventive hormone therapy. Ann Intern Med. 1992;117:1038–1041
  48. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992;117:1016–1037
  49. The Writing Group for the PEPI Trial . Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA. 1995;273:199–208
  50. Cushman M, Legault C, Barrett-Connor E, Stefanick ML, Kessler C, Judd HL, et al. Effect of Postmenopausal Hormones on Inflammation-sensitive Proteins: the Postmenopausal Estrogen–Progestin Interventions (PEPI) Study. Circulation. 1999;100:717–722
  51. Hodis HN, Mack WJ, Lobo RA, Shoupe D, Sevanian A, Mahrer PR, et al. Estrogen in the prevention of atherosclerosis: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2001;135:939–953
  52. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/Progestin Replacement Study Follow-up (HERS II). JAMA. 2002;288(1):49–57
  53. Barrett-Connor E, Grady D, Stefanick ML. The rise and fall of menopausal hormone therapy. Ann Rev Public Health. 2005;26:16.1–16.26
  54. Herrington DM, Reboussin DM, Brosnihan KB, Sharp PC, Shumaker SA, Snyder TE, et al. Effects of estrogen replacement on the progression of coronary–artery atherosclerosis. N Engl J Med. 2000;343:522–529
  55. Viscoli DM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med. 2001;345:1243–1249
  56. Mosca L, Collins P, Herrington DM, Mendelsohn ME, Pasternak RC, Robertson RM, et al. Disease: a statement for healthcare professionals from the American Heart Association. Circulation. 2001;104:499–503
  57. Hersh AL, Stefanick ML, Stafford RS. National use of post-menopausal hormone therapy: annual trends and response to recent evidence, 1995–2003. JAMA. 2004;291:47–53
  58. The Women's Health Initiative Group . Design of the Women's Health Initiative clinical trial and observational study. Control Clin Trials. 1998;19:61–109
  59. Anderson GL, Kooperberg C, Geller N, Rossouw JE, Pettinger M, Prentice RL. Monitoring and reporting of the Women's Health Initiative randomized hormone therapy trials. Clin Trials. 2007;4:207–217
  60. Stefanick ML, Hsai J, Barad D, Johnson SJ, Cochrane B, Liu J. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Ann Epidemiol. 2003;13(9):S78–S86Suppl. I
  61. Cushman M, Kuller LH, Prentice R, Rodabough RJ, Psaty BM, Stafford RS, et al. Estrogen plus progestin and risk of venous thrombosis. JAMA. 2004;292:1573–1580
  62. Curb JD, Prentice RL, Bray PR, Langer RD, van Horn L, Barnabei V, et al. Venous thromboembolism and conjugated equine estrogen in women without a uterus. Arch Intern Med. 2006;166:772–780
  63. Canonico M, Plu-Bureau G, Lowe GDO, Scarabin P-Y. Hormone replacement therapy and risk of venous thromoembolism in postmenopausal women: systematic review and meta-analysis. BMJ. 2008;336:1227–1231
  64. Huang Aj, Sawaya GF, Vittinhoff E, Lin F, Grady D. Hot flushes, coronary heart disease, and hormone therapy in postmenopausal women. Menopause. 2009;16:639–643
  65. Col NF, Pauker SG. The discrepancy between observational studies and randomized trials of menopausal hormone therapy: did expectations shape experience?. Ann Intern Med. 2003;139:923–929
  66. Humphrey LL, Chan BKS, Sox HC. Postmenopausal hormone replacement therapy and the primary prevention of cardiovascular disease. Ann Intern Med. 2002;137:273–284
  67. Prentice R, Langer R, Stefanick ML, Howard B, Pettinger M, Anderson G, et al. Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial. Am J Epidemiol. 2005;162:1–11
  68. Prentice RL, Langer RD, Stefanick ML, Howard BV, Pettinger M, Anderson GL, et al. Combined analysis of Women's Health Initiative observational and clinical trial data on postmenopausal hormone treatment and cardiovascular disease. Am J Epidemiol. 2006;163:589–599
  69. Mosca L, Banda CL, Benjamin EJ, Berra K, Bushnell C, Dolor RJ, et al. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation. 2007;115:1481–1501
  70. Strong JP, Malcom GT, McMahan CA, et al. Prevalence and extent of atherosclerosis in adolescents and young adults: implications for prevention from the pathobiological determinants of atherosclerosis in youth study. JAMA.

PII: S0939-4753(10)00064-5

doi: 10.1016/j.numecd.2010.02.015

Nutrition, Metabolism & Cardiovascular Diseases
Volume 20, Issue 6 , Pages 451-458 , July 2010

Article Tools